In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $40.03 in the prior trading day, Conmed Corp (NYSE: CNMD) closed at $41.58, up 3.87%. In other words, the price has increased by $3.87 from its previous closing price. On the day, 0.59 million shares were traded. CNMD stock price reached its highest trading level at $42.085 during the session, while it also had its lowest trading level at $40.02.
Ratios:
Our goal is to gain a better understanding of CNMD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 33.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.64. For the most recent quarter (mrq), Quick Ratio is recorded 0.95 and its Current Ratio is at 2.10. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.85.
On April 28, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $55.
JP Morgan Downgraded its Overweight to Neutral on February 06, 2025, whereas the target price for the stock was revised from $85 to $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 21 ’25 when Glaze Richard sold 257 shares for $41.21 per share. The transaction valued at 10,591 led to the insider holds 0 shares of the business.
Glaze Richard bought 257 shares of CNMD for $10,591 on Nov 21 ’25. On Nov 06 ’25, another insider, Garner Todd W, who serves as the Executive Vice President & CFO of the company, sold 3,500 shares for $43.00 each. As a result, the insider received 150,500 and left with 1,836 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNMD now has a Market Capitalization of 1287647616 and an Enterprise Value of 2102471552. As of this moment, Conmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.19, and their Forward P/E ratio for the next fiscal year is 9.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.96 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 1.56 whereas that against EBITDA is 9.309.
Stock Price History:
The Beta on a monthly basis for CNMD is 0.97, which has changed by -0.40128624 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, CNMD has reached a high of $74.70, while it has fallen to a 52-week low of $38.32. The 50-Day Moving Average of the stock is -1.16%, while the 200-Day Moving Average is calculated to be -16.39%.
Shares Statistics:
The stock has traded on average 539.99K shares per day over the past 3-months and 628550 shares per day over the last 10 days, according to various share statistics. A total of 30.96M shares are outstanding, with a floating share count of 30.03M. Insiders hold about 3.04% of the company’s shares, while institutions hold 109.21% stake in the company. Shares short for CNMD as of 1767139200 were 2357218 with a Short Ratio of 4.37, compared to 1764288000 on 2321626. Therefore, it implies a Short% of Shares Outstanding of 2357218 and a Short% of Float of 10.39.
Dividends & Splits
In the trailing 12 months, CNMD’s forward annual dividend rate was 0.8, compared to 0.60 this year. Against a Trailing Annual Dividend Yield of 0.019985013. The stock’s 5-year Average Dividend Yield is 0.95. The current Payout Ratio is 18.82% for CNMD, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2001-09-10 when the company split stock in a 3:2 ratio.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Conmed Corp (CNMD) in the stock market.The consensus estimate for the next quarter is $0.94, with high estimates of $1.0 and low estimates of $0.88.
Analysts are recommending an EPS of between $4.51 and $4.48 for the fiscal current year, implying an average EPS of $4.5. EPS for the following year is $4.46, with 6.0 analysts recommending between $4.95 and $4.15.
Revenue Estimates
6 analysts predict $366.88M in revenue. The current quarter. It ranges from a high estimate of $368.5M to a low estimate of $365.94M. As of. The current estimate, Conmed Corp’s year-ago sales were $345.94MFor the next quarter, 6 analysts are estimating revenue of $330.02M. There is a high estimate of $342.35M for the next quarter, whereas the lowest estimate is $317.68M.
A total of 6 analysts have provided revenue estimates for CNMD’s current fiscal year. The highest revenue estimate was $1.37B, while the lowest revenue estimate was $1.37B, resulting in an average revenue estimate of $1.37B. In the same quarter a year ago, actual revenue was $1.31BBased on 6 analysts’ estimates, the company’s revenue will be $1.38B in the next fiscal year. The high estimate is $1.44B and the low estimate is $1.34B.
